Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 32.52M P/E - EPS this Y 28.10% Ern Qtrly Grth -
Income -19.02M Forward P/E -2.74 EPS next Y 14.10% 50D Avg Chg -8.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 3.00%
Dividend N/A Price/Book 2.37 EPS next 5Y - 52W High Chg -39.00%
Recommedations 2.00 Quick Ratio 6.65 Shares Outstanding 27.45M 52W Low Chg 194.00%
Insider Own 40.18% ROA -56.85% Shares Float 14.50M Beta 0.17
Inst Own 17.86% ROE -103.81% Shares Shorted/Prior 479.69K/568.37K Price 2.00
Gross Margin - Profit Margin - Avg. Volume 257,740 Target Price 7.00
Oper. Margin - Earnings Date Nov 9 Volume 49,984 Change -2.44%
About Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc. News
12/19/24 Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
12/16/24 Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
12/10/24 Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
12/10/24 Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
12/09/24 Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
11/25/24 Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
10/02/24 Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
09/19/24 Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
08/29/24 Immix Biopharma Independent Director Acquires 2.6% More Stock
08/28/24 Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
08/19/24 What Makes Immix Biopharma (IMMX) a New Buy Stock
07/25/24 California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
07/08/24 Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
07/03/24 Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
06/17/24 Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
05/23/24 Immix Biopharma Insiders Placed Bullish Bets Worth US$625.7k
05/10/24 Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
04/29/24 Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
04/18/24 Immix Biopharma on Track to Dose NXC-201 Patients in United States
04/15/24 Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
IMMX Chatroom

User Image fightmebro Posted - 1 day ago

$IMMX trash

User Image keebs107 Posted - 1 day ago

$IMMX

User Image Thestocktraderhubzee Posted - 4 days ago

WATCHLIST DEC 20 2024. $KMI Kinder Morgan shares are trading higher after the company's Tennessee Gas Pipeline subsidiary announced its decision to proceed with its Mississippi Crossing Project. $MYNZ Mainz Biomed shares are trading higher after the company announced it formed an agreement with Quest Diagnostics to support the commercialization of its next-gen screening test for colorectal cancer. $SLB Citigroup Maintains Buy on Schlumberger, Lowers Price Target to $50 $CGTX B. Riley Securities Upgrades Cognition Therapeutics to Buy, Raises Price Target to $1.5 $IMMX Immix Biopharma Announces Initial Data From First Four Patients In NEXICART-2 US Study; Says All Four Patients Treated With NXC-201 Normalized Disease Markers Within 30 Days Of Dosing, Of Which, Two Are Already Classified As Complete

User Image Expert33 Posted - 4 days ago

$IMMX We got a sleeper here...33,000 patients in the U.S. You do the math

User Image Daddy044 Posted - 5 days ago

$IMMX Very promising

User Image keebs107 Posted - 5 days ago

$IMMX Please make my 2.5 calls safe mr MM.

User Image DD_investments Posted - 5 days ago

$IMMX crazy day 😂

User Image Jtyler21 Posted - 5 days ago

$IMMX why the drop??

User Image LongBallll87 Posted - 5 days ago

$IMMX nothing to see here, just your typical 25% sell off from the day high.

User Image _www_larval_com_ Posted - 5 days ago

$IMMX has stumbled -15% lower to -4% (~122Kv) in the last few minutes, 12/20 options, follow for more volatility.

User Image Dingalingading Posted - 5 days ago

$IMMX

User Image Thestocktraderhubzee Posted - 5 days ago

$IMMX Immix Biopharma Announces Initial Data From First Four Patients In NEXICART-2 US Study; Says All Four Patients Treated With NXC-201 Normalized Disease Markers Within 30 Days Of Dosing, Of Which, Two Are Already Classified As Complete

User Image DARKP00L Posted - 5 days ago

$IMMX ﹩2.34 - Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis #pennystock #stockmarket #lowfloat #stockstotrade #stockscanner #tradinginsights #NYSE #darkpools

User Image Ssssskkkk Posted - 5 days ago

$IMMX The anticipated release date for IMMX’s additional data is approaching. Please note that this is a personal estimate and is not affiliated with the company’s official position. Expected dates: December 18th or 19th (pre-market). If no announcement is made this week, December 25th or 26th appears to be the most likely timeframe. This suggests that the company’s announcement is imminent.

User Image Ssssskkkk Posted - 5 days ago

$IMMX The anticipated release date for IMMX’s additional data is approaching. Please note that this is a personal estimate and is not affiliated with the company’s official position. Expected dates: December 19th or 20th (pre-market). If no announcement is made this week, December 26th or 27th appears to be the most likely timeframe. This suggests that the company’s announcement is imminent.

User Image TrumpXTrades Posted - 6 days ago

$IMMX US news is dropping soon. We’ll get there. This has been a turtle race. Buy those 7-12% dips

User Image Twins_poppa Posted - 6 days ago

$IMMX someone bought 42k shares at $2.18 😮

User Image Twins_poppa Posted - 1 week ago

$IMMX was $1.88 a good entry? When $1.50s was the 52 week low maybe. After the new 52 week low of $1.25 maybe not.

User Image keebs107 Posted - 1 week ago

$IMMX sold 20 12/20 2.5c for .30 and will buy more shares when they expire. Wash and repeat

User Image eddoetwoshoes Posted - 1 week ago

$IMMX So why the drop? Today's news looks promising. https://finance.yahoo.com/news/journal-clinical-oncology-publishes-nxc-144800583.html Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling c...

User Image Expert33 Posted - 1 week ago

$IMMX I am so glad this is dropping again...

User Image keebs107 Posted - 1 week ago

$IMMX

User Image Dingalingading Posted - 1 week ago

$IMMX

User Image Expert33 Posted - 1 week ago

$IMMX https://immixbio.com/journal-of-clinical-oncology-publishes-nxc-201-positive-clinical-results-in-relapsed-refractory-al-amyloidosis/

User Image Naturallaws Posted - 1 week ago

$IMMX someone please report my post below. I tried to delete it, but am unable. So very sorry for my confusion.

User Image Naturallaws Posted - 1 week ago

$IMMX Same company, under a different name, touted 100% success in a mouse study of a universal flu vaccine. They followed up with seven consecutive "successful" phase 2 human studies. They leaked teasing indicators of success for their large phase 3, which ended up as a total, abject failure when the actual data was finally revealed. To my mind, this is not a group I would consider to be particularly high on any scale measuring integrity.

User Image Expert33 Posted - 1 week ago

$IMMX $IMMX My goal is to have more shares than that goofball @ShortKillerMD...

User Image fightmebro Posted - 1 week ago

$IMMX where we going with this

User Image fightmebro Posted - 1 week ago

$IMMX

User Image SpankDaBank Posted - 1 week ago

$IMMX

Analyst Ratings
HC Wainwright & Co. Buy Aug 19, 24
HC Wainwright & Co. Buy Jul 26, 24
HC Wainwright & Co. Buy Jul 9, 24
HC Wainwright & Co. Buy Jul 1, 24
Roth MKM Buy Aug 14, 23
Roth MKM Buy Feb 22, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Hsu Jason Director Director Dec 08 Buy 4.78 56,000 267,680 813,000 12/12/23
Hsu Jason Director Director Sep 11 Buy 2.7 72,000 194,400 757,000 09/18/23
Ng Carey Director Director Sep 14 Buy 2.576 10,000 25,760 10,000 09/15/23
Adams Helen C. Director Director Sep 12 Buy 2.9609 13,000 38,492 13,000 09/14/23
Hsu Jason Director Director Sep 08 Buy 2.5317 10,000 25,317 685,000 09/12/23
BUCHAN MELISSA JANE Director Director Sep 07 Buy 2.4613 20,000 49,226 20,000 09/11/23
Marquet Magda Director Director Sep 06 Buy 2.4681 9,000 22,213 20,000 09/08/23
Marquet Magda Director Director Aug 31 Buy 2.01 1,000 2,010 1,000 09/05/23
Senn Sean 10% Owner 10% Owner Jul 14 Sell 2.75 200 550 899,800 07/18/22